Literature DB >> 2918720

Clinical and histopathological appraisal of preoperative irradiation for adenocarcinoma of the pancreatoduodenal region.

O Ishikawa1, H Ohhigashi, T Teshima, M Chatani, T Inoue, S Tanaka, T Kitamura, A Wada, Y Sasaki, S Imaoka.   

Abstract

A retrospective review to elucidate the rationale of preoperative irradiation was made on 18 carcinomas of the head of the pancreas area. After 50 Gy/25 fractions of 10 MV X-ray was given, all 18 tumors decreased from 3.3 +/- 0.8 cm to 2.0 +/- 0.7 cm. At the surgical operation, 16 patients (89%) received pancreatic resection, without operative death. Histologically, in 13 of these 16 cases, the population of severely degenerative cancer cells (SDCC) was more than 1/3 of all cancer cells, and SDCCs were likely to locate at the periphery (advancing point of carcinoma). These histological patterns were considered as favorable to improve the operative curability. However, in the remaining three cases, the SDCC population was less than 1/3. In addition, nonaffected (i.e., viable) cancer cells were detected at the periphery, and this is an extremely adverse condition for subsequent surgery. Chronic pancreatitis in the noncancerous area was present in these three cases, but not in the 13 cases. Therefore, the most significant factor that predicts the radioresistance especially at the periphery of the carcinoma was considered to be coexisting chronic pancreatitis.

Entities:  

Mesh:

Year:  1989        PMID: 2918720     DOI: 10.1002/jso.2930400303

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  16 in total

Review 1.  Pathologic assessment of gastrointestinal tract and pancreatic carcinoma after neoadjuvant therapy.

Authors:  Reetesh K Pai; Rish K Pai
Journal:  Mod Pathol       Date:  2017-08-04       Impact factor: 7.842

2.  Guidelines for the management of patients with pancreatic cancer periampullary and ampullary carcinomas.

Authors: 
Journal:  Gut       Date:  2005-06       Impact factor: 23.059

Review 3.  Modern surgical treatment of pancreatic cancer.

Authors:  H Ozaki
Journal:  Int J Pancreatol       Date:  1994 Oct-Dec

4.  Investigational Strategies for Detection and Intervention in Early-Stage Pancreatic Cancer. April 24-27, Annapolis, Maryland. Abstracts.

Authors: 
Journal:  Int J Pancreatol       Date:  1994 Oct-Dec

5.  En bloc resection for locally advanced cancer of the pancreas: is it worthwhile?

Authors:  Aaron R Sasson; John P Hoffman; Eric A Ross; Steven A Kagan; James F Pingpank; Burton L Eisenberg
Journal:  J Gastrointest Surg       Date:  2002 Mar-Apr       Impact factor: 3.452

6.  Neoadjuvant chemotherapy in borderline resectable pancreatic cancer: A case report.

Authors:  Maria Celeste Palmarocchi; Ruben Carlo Balzarotti Canger; Piercarlo Saletti
Journal:  Oncol Lett       Date:  2017-04-11       Impact factor: 2.967

7.  Recurrent disease after microscopically radical (R0) resection of periampullary adenocarcinoma in patients without adjuvant therapy.

Authors:  Steve M M de Castro; Koert F D Kuhlmann; N Tjarda van Heek; Olivier R C Busch; G Johan Offerhaus; Thomas M van Gulik; Hugo Obertop; Dirk J Gouma
Journal:  J Gastrointest Surg       Date:  2004-11       Impact factor: 3.452

8.  Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: analysis of histopathology and outcome.

Authors:  Aaron R Sasson; R Wesley Wetherington; John P Hoffman; Eric A Ross; Harry Cooper; Neal J Meropol; Gary Freedman; James F Pingpank; Burton L Eisenberg
Journal:  Int J Gastrointest Cancer       Date:  2003

9.  Stroma composition and proliferative activity are related to therapy response in neoadjuvant treated pancreatic ductal adenocarcinoma.

Authors:  Lena Haeberle; Andrea Cacciato Insilla; Anne-Christine Kapp; Katja Steiger; Anna Melissa Schlitter; Björn Konukiewitz; Ihsan Ekin Demir; Helmut Friess; Irene Esposito
Journal:  Histol Histopathol       Date:  2021-03-26       Impact factor: 2.303

10.  Impact of histological response after neoadjuvant therapy on podocalyxin as a prognostic marker in pancreatic cancer.

Authors:  Annika Eurola; Ari Ristimäki; Harri Mustonen; Anna-Maria Nurmi; Jaana Hagström; Caj Haglund; Hanna Seppänen
Journal:  Sci Rep       Date:  2021-05-10       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.